2014 EASO Position Statement on the Use of Anti-Obesity Drugs

Obesity: A Review of Pathogenesis and Management Strategies in Adult

“…If weight loss achieved is satisfactory (>5% weight loss in non-diabetic and >3% in diabetic patients), treatment should be continued. 49,[70][71][72][73] Treatment should be discontinued in non-responders.…”

“…If a patient does not reach this target, the drug should be discontinued. [70][71][72][73]78,79 The efficacy and safety of the drug were assessed in the following RCTs: BLOOM 65 , BLOOM-DM 80 and BLOSSOM 81 . In the BLOOM-DM trial, both fasting blood glucose and haemoglobin A1C (HbA1c) levels were improved.…”

“…If a patient does not reach this target, the drug should be discontinued. [70][71][72][73] The efficacy and safety of the drug were assessed in the following RCTs: EQUIP 84 , CONQUER 67 , SEQUEL 85 and EQUATE 86 . Adverse events associated with treatment were dry mouth, constipation, insomnia, palpitations, dizziness, paraesthesia, disturbances in attention, metabolic acidosis and renal calculi, headache, dysgeusia (distortion of sense of taste), alopecia and hypokalaemia.…”

“…Adverse events associated with treatment were dry mouth, constipation, insomnia, palpitations, dizziness, paraesthesia, disturbances in attention, metabolic acidosis and renal calculi, headache, dysgeusia (distortion of sense of taste), alopecia and hypokalaemia. [70][71][72][73]87 The combination is contraindicated during pregnancy due to its teratogenic potential. Owing to this risk, the drug has been approved with a risk evaluation and mitigation strategy recommendation by the FDA.…”

“…If a patient does not reach this target, the drug should be discontinued. [70][71][72][73]89 The efficacy and safety of the drug were assessed in the following RCTs: COR-I 66 , COR-II 90 , COR-BMOD 91 and COR-DM 92 . Nausea, headache, dizziness, insomnia and vomiting were the most common adverse events that led to discontinuation.…”